Hormone receptors and other prognostic factors in breast cancer in Cuba.
Clinical management of breast cancer, making a prognosis and deciding on treatment, currently depend on defining prognostic factors, especially hormone receptors (HR). In addition to confirming the heterogeneity of the disease, these biological parameters are indispensable tools for designing personalized treatment. In this study, 1509 tumors from Cuban women diagnosed with breast cancer were examined. Hormone receptor (HR) expression was determined and correlated with a group of prognostic factors, such as age, tumor size, histological type, nuclear grade, histological grade, number of metastatic axillary lymph nodes, and clinical stage. Estrogen receptor (ER) expression was associated with low nuclear grade and histological grade, and with smaller tumor size (p < 0.05). Analysis of age at the time of diagnosis showed that ER expression was greater in patients in the group aged >50 years (p < 0.05). In general, ER expression was greater in patients in earlier clinical stages (p < 0.05). With regard to HR expression, 53% of tumors in this sample were ER+ and 49% were PR+. In 38% of cases, both receptors were positive and in 28% both receptors proved negative. The ER+/PR- combination was observed in 23% of cases while only 11% exhibited the ER-/PR+ combination. These findings indicate that approximately 72% of the tumors studied expressed some level of hormone dependency. This is the first report of HR expression in Cuba using immunohistochemical techniques and a representative sample of breast tumors diagnosed in different provinces around the country.
Alvarez Goyanes
Rosa Irene
RI
Experimental Research, National Oncology and Radiobiology Institute, Havana, Cuba. ialvarez@infomed.sld.cu
Escobar Pérez
Xiomara
X
Camacho Rodríguez
Rolando
R
Orozco López
Maybi
M
Franco Odio
Sonia
S
Llanes Fernández
Leticia
L
Guerra Yi
Martha
M
Rodríguez Padilla
Cristina
C
D001943:Breast Neoplasms / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone